Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenxianshengmai Oral Liquid is a Traditional Chinese Medicine (TCM) herbal formulation developed and manufactured by Shaanxi Buchang Pharmaceutical. It is composed of eight specific herbal ingredients: *Panax ginseng*, *Epimedium brevicornu*, *Psoralea corylifolia*, *Lycium barbarum*, *Ephedra intermedia*, *Asarum sieboldii*, *Salvia miltiorrhiza*, and *Whitmania pigra*. The drug is approved in China (CFDA approval number Z20080183) for the treatment of cardiac and cerebral vascular diseases, specifically targeting conditions such as sick sinus syndrome, sinus bradyarrhythmias, and bradycardia. Mechanistically, the formulation works by increasing heart rate and improving sinoatrial node conduction time through the modulation of the PKC/NOX-2 signaling pathway, regulation of cardiac ion channels and ATPases, and reduction of oxidative stress. It has also demonstrated protective effects against myocardial ischemia-reperfusion injury.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenxianshengmai Oral Liquid.